Clinical Trial

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is to assess the safety and tolerability, obtain the recommended phase 2 dose(RP2D)/or Maximum Tolerated Dose (MTD) for LM-2417 as a single agent or in combination with other anti-tumour agents in subjects with advanced solid tumours.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-11-07; most recent amendment 2025-09-21.
Status change: Not Yet Recruiting → Recruiting 2025-09-21
Trial Details
NCT Number NCT06682780
Lead Sponsor LaNova Medicines Limited
Conditions Advanced Solid Tumor
Enrollment 320 participants
Start Date 2025-09-17
Primary Completion 2028-12-25 (estimated)
Study Completion 2029-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-25